347 related articles for article (PubMed ID: 25312018)
21. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.
Zelei T; Molnár MJ; Szegedi M; Kaló Z
Orphanet J Rare Dis; 2016 Jun; 11(1):72. PubMed ID: 27259284
[TBL] [Abstract][Full Text] [Related]
22. Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007.
Orofino J; Soto J; Casado MA; Oyagüez I
Appl Health Econ Health Policy; 2010; 8(5):301-15. PubMed ID: 20804223
[TBL] [Abstract][Full Text] [Related]
23. Modifying the Criteria for Granting Orphan Drug Market Exclusivity.
Socal MP; Parasrampuria S; Anderson GF
Value Health; 2020 Nov; 23(11):1470-1476. PubMed ID: 33127018
[TBL] [Abstract][Full Text] [Related]
24. How can the risk that orphan drugs present to budgets be managed better?
O'Neill C
Clin Ther; 2010 Aug; 32(9):1640-1. PubMed ID: 20974321
[No Abstract] [Full Text] [Related]
25. FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis.
Michaeli T; Jürges H; Michaeli DT
BMJ; 2023 May; 381():e073242. PubMed ID: 37160306
[TBL] [Abstract][Full Text] [Related]
26. Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013.
Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
J Med Econ; 2010; 13(2):295-301. PubMed ID: 20482245
[TBL] [Abstract][Full Text] [Related]
27. Market uptake of orphan drugs--a European analysis.
Picavet E; Annemans L; Cleemput I; Cassiman D; Simoens S
J Clin Pharm Ther; 2012 Dec; 37(6):664-7. PubMed ID: 22731105
[TBL] [Abstract][Full Text] [Related]
28. Limits on use of health economic assessments for rare diseases.
Hyry HI; Stern AD; Cox TM; Roos JC
QJM; 2014 Mar; 107(3):241-5. PubMed ID: 24453281
[TBL] [Abstract][Full Text] [Related]
29. Estimating the clinical cost of drug development for orphan versus non-orphan drugs.
Jayasundara K; Hollis A; Krahn M; Mamdani M; Hoch JS; Grootendorst P
Orphanet J Rare Dis; 2019 Jan; 14(1):12. PubMed ID: 30630499
[TBL] [Abstract][Full Text] [Related]
30. Estimating the budget impact of orphan drugs in Sweden and France 2013-2020.
Hutchings A; Schey C; Dutton R; Achana F; Antonov K
Orphanet J Rare Dis; 2014 Feb; 9():22. PubMed ID: 24524281
[TBL] [Abstract][Full Text] [Related]
31. Orphan drugs for rare diseases: is it time to revisit their special market access status?
Simoens S; Cassiman D; Dooms M; Picavet E
Drugs; 2012 Jul; 72(11):1437-43. PubMed ID: 22747423
[TBL] [Abstract][Full Text] [Related]
32. Drug development for exceptionally rare metabolic diseases: challenging but not impossible.
Putzeist M; Mantel-Teeuwisse AK; Wied CC; Hoes AW; Leufkens HG; de Vrueh RL
Orphanet J Rare Dis; 2013 Nov; 8():179. PubMed ID: 24237580
[TBL] [Abstract][Full Text] [Related]
33. Orphan drugs revisited.
McCabe C; Tsuchiya A; Claxton K; Raftery J
QJM; 2006 May; 99(5):341-5; discussion 350-1. PubMed ID: 16504983
[No Abstract] [Full Text] [Related]
34. Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?
Brabers AE; Moors EH; van Weely S; de Vrueh RL
Orphanet J Rare Dis; 2011 Sep; 6():59. PubMed ID: 21892964
[TBL] [Abstract][Full Text] [Related]
35. Adopting an orphan.
Rinaldi A
EMBO Rep; 2005 Jun; 6(6):507-10. PubMed ID: 15940282
[TBL] [Abstract][Full Text] [Related]
36. The quality of economic evaluations of ultra-orphan drugs in Europe - a systematic review.
Schuller Y; Hollak CE; Biegstraaten M
Orphanet J Rare Dis; 2015 Jul; 10():92. PubMed ID: 26223689
[TBL] [Abstract][Full Text] [Related]
37. Access to orphan drugs in western Europe: can more systematic policymaking really help to avoid different decisions about the same drug?
Kanters TA; Hakkaart L; Rutten-van Mölken MP; Redekop WK
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):557-9. PubMed ID: 25973903
[TBL] [Abstract][Full Text] [Related]
38. [Orphan diseases and orphan medicines: a Belgian and European study].
Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
J Pharm Belg; 2009 Dec; (4):131-7. PubMed ID: 20183989
[TBL] [Abstract][Full Text] [Related]
39. [Orphan drugs: drugs for rare diseases].
Schenk M
Dtsch Med Wochenschr; 2010 May; 135(18):p17. PubMed ID: 20455291
[No Abstract] [Full Text] [Related]
40. [Orphan drugs: some legal, ethical and economics aspects].
Pabst JY
Rev Epidemiol Sante Publique; 2001 Sep; 49(4):387-96. PubMed ID: 11567205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
